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Purpose of the study
The CASTLE study showed no significant differences in
the percent of patients with viral load <,50 copies/ml or in
CD4+ T-cell count increase at 48 weeks for the two antiret-
roviral (ARV) treatment regimens. Total cholesterol (TC)
levels were elevated in 18% and 7% of patients receiving
lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir
(ATV+RTV) respectively. However, the economic impact
of these findings is not known. The purpose of this study
was to conduct a CEA and budget impact analysis compar-
ing LPV/r and ATV+RTV for a group of antiretroviral-naïve
patients with a baseline CD4+ T-cell distribution and TC
profile similar to the CASTLE population.
Methods
This decision analysis study used a previously published
Markov model of HIV disease, incorporating coronary
heart disease (CHD) events to compare the short- and
long-term budget impacts and CHD consequences
expected for the two regimens.
Summary of results
The basic assumption was a baseline CHD risk of 4.6%
and that 50% of the population in the CASTLE study were
smokers. The CHD risk differences in favor of ATV+RTV
resulted in an average improvement in life expectancy of
0.031 QALYs (11 days), and an incremental cost-effective-
ness ratio of $1,409,734/QALY. Use of the LPV/r regimen
saved $24,518 and $36,651 at 5 and 10 years, respec-
tively, with lifetime cost savings estimated at $38,490. A
sensitivity analysis using a cohort of all smokers on anti-
hypertensive medication estimated the TC difference
between the regimens at 48 weeks resulting in an average
improvement in life expectancy of 0.088 QALYs (32 days)
in favor of ATV+RTV, and cost-effectiveness ratio of
$520,861/QALY.
Conclusion
The use of an ATV+RTV-based regimen in ARV-naïve
patients with a CHD risk similar to patients in the CASTLE
study is not a cost-effective use of scarce resources. The
very small added CHD risk incurred by LPV/r treatment is
more than offset by its short- and long-term cost savings.
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